#USA #International Isotopes #Idaho Falls #Cobalt Products #Nuclear Medicine Standards

International Isotopes Inc. Reports Significant Financial Results

International Isotopes Inc. (OTCQB: INIS), headquartered in Idaho Falls, Idaho, has announced impressive financial results for the second quarter and the first six months ending June 30, 2025. The company's strategic focus on the development and distribution of nuclear medicine and radiopharmaceutical products is clearly paying off.

Overview of Financial Performance

For the second quarter of 2025, International Isotopes reported a revenue of $3,655,320, reflecting a robust 15.3% increase compared to the same quarter the previous year. Over the first half of 2025, total revenue reached $6,894,220, showing a substantial 13.5% growth or $820,529 up from the prior year. This growth in sales is largely attributed to increased demand for Nuclear Medicine Standards products, which have gained traction in the medical field.

Despite facing challenges in some product segments, the net loss for the second quarter has improved to $160,785, compared to $233,445 for the same quarter last year—a remarkable improvement of 27%. The net loss for the first half of the year was reduced by 29.4% to $273,479.

Key Growth Drivers

Shahe Bagerdjian, the President and CEO of International Isotopes, expressed satisfaction with the company’s trajectory, “We are pleased with our sales growth, noting a 15% increase for the current quarter and a 13.5% growth for the first six months of 2025. We continue to expect a solid second half of 2025,” he stated, highlighting the anticipated seasonal demand for Cobalt products and the upcoming launch of new offerings.

Product Segment Analysis

1. Theranostics Products

Revenue from Theranostics Products saw a decline, earning $3,692,233 in the first half of 2025, down from $4,074,213 the prior year. This decline of 9% was due to losing some standing order customers but remains a critical area of focus.

2. Nuclear Medicine Standards

The Nuclear Medicine Standards segment witnessed remarkable growth, with sales jumping to $2,340,580 in the first six months, a staggering 99% increase from $1,173,311 the previous year. This surge is largely attributed to alleviating the global shortage of the Cobalt-57 isotope, which significantly impacted the company's product availability.

3. Cobalt Products

Cobalt Products revenue fell to $750,465, down 9% from $826,167 for the same period last year. The fluctuation in Cobalt product sales was attributed to the timing of large-value sales of Cobalt-60 sources, which typically occur seasonally.

4. Medical Devices

For the first half of 2025, the recently established Medical Devices segment generated $58,089 in revenue, representing a new frontier for the company. The Swirler® and Tru-Fit™ mouthpieces, alongside investments in automation and joint ventures, indicate a robust expansion strategy moving forward.

Looking Ahead

International Isotopes Inc. is optimistic about maintaining this growth trajectory. The company anticipates strong sales performance for Cobalt products in the latter half of the fiscal year and looks forward to the introduction of new products under the RadQual and PhanQual brands, which are expected to enhance its market presence.

In summary, International Isotopes Inc. is navigating its way through a competitive industry landscape by leveraging opportunities in nuclear medicine and medical device sectors, reflecting both resilience and innovation in its operations. Investors and stakeholders remain optimistic as the company strengthens its footing in the global market.

For more detailed financial metrics and updates, visit International Isotopes Investor Center.